MICARDIS® and Valsartan in Patients With Mild-to-Moderate Hypertension Using Ambulatory Blood Pressure Monitoring
Primary Purpose
Hypertension
Status
Completed
Phase
Phase 3
Locations
Study Type
Interventional
Intervention
Telmisartan
Valsartan
Placebo
Sponsored by

About this trial
This is an interventional treatment trial for Hypertension
Eligibility Criteria
Inclusion Criteria:
- Mild to moderate hypertension defined as mean seated diastolic blood pressure measurement of ≥ 95 mm Hg and ≤ 114 mm Hg, measured by manual cuff sphygmomanometer, on the last visit (Visit 6) of the four-week placebo run-in period (baseline BP)
- Mean seated systolic blood pressure ≥ 140 mm Hg and ≤ 200 mm Hg, measured by manual cuff at Visit 6 (baseline BP)
- A 24-hour mean ABPM measurement of ≥ 130/85 mm Hg evaluated at Visit 7 (baseline ABPM)
- Age 18 or older
- Ability to provide written informed consent
Exclusion Criteria:
Pre-menopausal women (last menstruation ≤ 1 year prior to start of screening):
- Who are not surgically sterile (hysterectomy, tubal ligation)
- Who are NOT practicing acceptable means of birth control or who do NOT plan to continue using an acceptable method throughout the study. Acceptable methods of birth control include IUD (intrauterine device), oral, implantable or injectable contraceptives
Any woman:
- Who has a positive serum pregnancy test at screening (Visit 1) or baseline (Visit 7)
- Who is nursing
Hepatic and/or renal dysfunction as defined by the following laboratory parameters
- SGPT (ALT) (serum glutamate pyruvate transaminase) or SGOT (AST) (serum glutamate oxaloacetate transaminase) greater than two times the upper limit of normal
- Serum creatinine > 2.3 mg/dL
- At screening (Visit 1): clinically relevant sodium depletion, hyperkalemia, or hypokalemia
- Known or suspected secondary hypertension
- Bilateral renal artery stenosis; renal artery stenosis in a solitary kidney; post-renal transplant patients, presence of only one functioning kidney
- Congestive heart failure (NYHA (New York Heart Association) functional class CHF (congestive heart failure) III-IV
- Unstable angina within the past three months
- Stroke within the past six months
- Myocardial infarction or cardiac surgery within the past three months
- PTCA (percutaneous transluminal coronary angioplasty) within the past three months
- History of angioedema
- Sustained ventricular tachycardia, atrial fibrillation, atrial flutter or other clinically relevant cardiac arrhythmias as determined by the investigator
- Hypertrophic obstructive cardiomyopathy, aortic stenosis, hemodynamically relevant stenosis of the aortic or mitral valve
- Administration of digoxin or other digitalis-type drugs
- Patients with insulin-dependent diabetes mellitus whose diabetes has not been stable and controlled for at least the past three months as defined by HbA1C ≥ 10%
- Known drug or alcohol dependency within the past one year period
- Concomitant administration of medications known to affect blood pressure, except medications allowed by the protocol
- Night shift workers who routinely sleep during the daytime and whose work hours include midnight to 4:00 AM
- Patients receiving any investigational therapy within one month of signing the informed consent form. Note that patients who have participated in previous MICARDIS® (telmisartan) studies may participate in this study provided there has been at least one month between discontinuing the previous study and signing the consent for the present study
- Known hypersensitivity to any component of the formulations
- Any clinical condition which, in the opinion of the investigator, would not allow safe completion of the protocol and safe administration of trial medication
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
Telmisartan
Valsartan
Arm Description
Outcomes
Primary Outcome Measures
Changes from baseline in diastolic and systolic blood pressure during the last 6 hours of a 24-hour dosing interval measured by ambulatory blood pressure monitoring (ABPM)
Secondary Outcome Measures
Changes from baseline in diastolic and systolic blood pressures during other times during 24-hr ABPM profile
Changes from baseline in seated trough diastolic and systolic blood pressures as measured by manual cuff sphygmomanometer
Blood pressure responder rates based on ABPM
24-hour-mean diastolic blood pressure <= 80 mmHg and/or reduction from baseline of at least 10 mmHg or reduction from baseline in 24-hour-mean systolic blood pressure of at least 10 mmHg
Blood pressure responder rates based manual cuff measurements
24-hour-mean diastolic blood pressure <= 80 mmHg and/or reduction from baseline of at least 10 mmHg or reduction from baseline in 24-hour-mean systolic blood pressure of at least 10 mmHg
Number of patients with adverse events
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT02177396
Brief Title
MICARDIS® and Valsartan in Patients With Mild-to-Moderate Hypertension Using Ambulatory Blood Pressure Monitoring
Official Title
A Prospective Randomized Open-Label Blinded End Point (PROBE) Trial Comparing MICARDIS® (Telmisartan) (80 mg QD) and Valsartan (80 mg QD) in Patients With Mild-to-Moderate Hypertension Using Ambulatory Blood Pressure Monitoring.
Study Type
Interventional
2. Study Status
Record Verification Date
June 2014
Overall Recruitment Status
Completed
Study Start Date
April 1998 (undefined)
Primary Completion Date
December 1998 (Actual)
Study Completion Date
undefined (undefined)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Boehringer Ingelheim
4. Oversight
5. Study Description
Brief Summary
The primary aim of the trial was to compare the effect of telmisartan and valsartan in lowering ambulatory diastolic and/or systolic blood pressure in the last six hours of the dosing interval. Secondary variables included changes from baseline in diastolic and systolic blood pressures during other times during the 24-hour ABPM profile, changes from baseline in seated trough diastolic and systolic blood pressures as measured by manual cuff, and responder rates. Assessment of safety was also considered. Adverse events and use of concomitant therapies were monitored at each study visit. Blood pressure and heart rate were collected at each visit. Physical examination, electrocardiograms (ECG) and laboratory tests were completed during the trial as well.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hypertension
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
426 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Telmisartan
Arm Type
Experimental
Arm Title
Valsartan
Arm Type
Active Comparator
Intervention Type
Drug
Intervention Name(s)
Telmisartan
Intervention Type
Drug
Intervention Name(s)
Valsartan
Intervention Type
Drug
Intervention Name(s)
Placebo
Primary Outcome Measure Information:
Title
Changes from baseline in diastolic and systolic blood pressure during the last 6 hours of a 24-hour dosing interval measured by ambulatory blood pressure monitoring (ABPM)
Time Frame
Day 1 and 56 of the open-label period
Secondary Outcome Measure Information:
Title
Changes from baseline in diastolic and systolic blood pressures during other times during 24-hr ABPM profile
Time Frame
Day 1 and 56 of the open-label period
Title
Changes from baseline in seated trough diastolic and systolic blood pressures as measured by manual cuff sphygmomanometer
Time Frame
Baseline (day 27 of the single-blind period), days 1, 14, 28, 56 and 57 of the open-label period
Title
Blood pressure responder rates based on ABPM
Description
24-hour-mean diastolic blood pressure <= 80 mmHg and/or reduction from baseline of at least 10 mmHg or reduction from baseline in 24-hour-mean systolic blood pressure of at least 10 mmHg
Time Frame
day 56 of the open-label period
Title
Blood pressure responder rates based manual cuff measurements
Description
24-hour-mean diastolic blood pressure <= 80 mmHg and/or reduction from baseline of at least 10 mmHg or reduction from baseline in 24-hour-mean systolic blood pressure of at least 10 mmHg
Time Frame
days 14, 28, 56 and 57 of the open-label period
Title
Number of patients with adverse events
Time Frame
up to 57 days
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Mild to moderate hypertension defined as mean seated diastolic blood pressure measurement of ≥ 95 mm Hg and ≤ 114 mm Hg, measured by manual cuff sphygmomanometer, on the last visit (Visit 6) of the four-week placebo run-in period (baseline BP)
Mean seated systolic blood pressure ≥ 140 mm Hg and ≤ 200 mm Hg, measured by manual cuff at Visit 6 (baseline BP)
A 24-hour mean ABPM measurement of ≥ 130/85 mm Hg evaluated at Visit 7 (baseline ABPM)
Age 18 or older
Ability to provide written informed consent
Exclusion Criteria:
Pre-menopausal women (last menstruation ≤ 1 year prior to start of screening):
Who are not surgically sterile (hysterectomy, tubal ligation)
Who are NOT practicing acceptable means of birth control or who do NOT plan to continue using an acceptable method throughout the study. Acceptable methods of birth control include IUD (intrauterine device), oral, implantable or injectable contraceptives
Any woman:
Who has a positive serum pregnancy test at screening (Visit 1) or baseline (Visit 7)
Who is nursing
Hepatic and/or renal dysfunction as defined by the following laboratory parameters
SGPT (ALT) (serum glutamate pyruvate transaminase) or SGOT (AST) (serum glutamate oxaloacetate transaminase) greater than two times the upper limit of normal
Serum creatinine > 2.3 mg/dL
At screening (Visit 1): clinically relevant sodium depletion, hyperkalemia, or hypokalemia
Known or suspected secondary hypertension
Bilateral renal artery stenosis; renal artery stenosis in a solitary kidney; post-renal transplant patients, presence of only one functioning kidney
Congestive heart failure (NYHA (New York Heart Association) functional class CHF (congestive heart failure) III-IV
Unstable angina within the past three months
Stroke within the past six months
Myocardial infarction or cardiac surgery within the past three months
PTCA (percutaneous transluminal coronary angioplasty) within the past three months
History of angioedema
Sustained ventricular tachycardia, atrial fibrillation, atrial flutter or other clinically relevant cardiac arrhythmias as determined by the investigator
Hypertrophic obstructive cardiomyopathy, aortic stenosis, hemodynamically relevant stenosis of the aortic or mitral valve
Administration of digoxin or other digitalis-type drugs
Patients with insulin-dependent diabetes mellitus whose diabetes has not been stable and controlled for at least the past three months as defined by HbA1C ≥ 10%
Known drug or alcohol dependency within the past one year period
Concomitant administration of medications known to affect blood pressure, except medications allowed by the protocol
Night shift workers who routinely sleep during the daytime and whose work hours include midnight to 4:00 AM
Patients receiving any investigational therapy within one month of signing the informed consent form. Note that patients who have participated in previous MICARDIS® (telmisartan) studies may participate in this study provided there has been at least one month between discontinuing the previous study and signing the consent for the present study
Known hypersensitivity to any component of the formulations
Any clinical condition which, in the opinion of the investigator, would not allow safe completion of the protocol and safe administration of trial medication
12. IPD Sharing Statement
Links:
URL
http://trials.boehringer-ingelheim.com/content/dam/internet/opu/clinicaltrial/com_EN/results/502/502.256_U99-3162.pdf
Description
Related Info
Learn more about this trial
MICARDIS® and Valsartan in Patients With Mild-to-Moderate Hypertension Using Ambulatory Blood Pressure Monitoring
We'll reach out to this number within 24 hrs